已收盤 11-20 16:00:00 美东时间
-0.050
-4.59%
11月21日,InflaRx(IFRX)收跌4.59%,报1.04美元,成交额50.15万美元,市值1.53亿美元。 行情数据 • 开盘价:1.06美元 • 最...
11-21 07:47
11月14日,InflaRx(IFRX)收跌5.65%,报1.17美元,成交额25.89万美元,市值1.72亿美元。 行情数据 • 开盘价:1.23美元 • 最...
11-14 07:44
11月13日,InflaRx(IFRX)收涨5.08%,报1.24美元,成交额106.89万美元,市值1.83亿美元。 行情数据 • 开盘价:1.21美元 •...
11-13 08:01
Izicopan achieved rapid and sustained inhibition of C5a/C5aR1 signaling Pharmacokinetic results demonstrated dose-dependent exposure, with izicopan well tolerated across all single and multiple doses evaluated Findings support Phase 2 development of izicopan in immune-inflammatory diseases Jena, G...
11-06 20:32
InflaRx announced positive Phase 1 clinical data for izicopan, an oral C5a receptor inhibitor, showing rapid and sustained inhibition of C5a/C5aR1 signaling, favorable pharmacokinetics, and strong safety profile across doses. The study, conducted in 86 healthy participants, supports Phase 2 development for immune-inflammatory diseases.
11-06 12:30
11月6日,InflaRx(IFRX)收跌8.45%,报1.35美元,成交额222.67万美元,市值2亿美元。 行情数据 • 开盘价:1.46美元 • 最高价...
11-06 07:39
InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.07) by 71.43 percent. This is a 90.48 percent increase over losses of $(0.21) per share from the same period last year.
11-03 21:14
10月30日,InflaRx(IFRX)收跌0.87%,报1.72美元,成交额53.37万美元,市值2.53亿美元。 行情数据 • 开盘价:1.74美元 • 最...
10-30 06:32
InflaRx N.V. has announced its November 2026 events, including participation in the Guggenheim Securities Healthcare Innovation Conference in Boston and the Jefferies Global Healthcare Conference in London. The company will also host a Capital Markets Day on November 3, 2026, featuring updates on its lead program izicopan for ANCA-associated vasculitis. Additionally, InflaRx will report its third-quarter 2026 financial results on the same day.
10-27 11:30
10月27日,InflaRx(IFRX)收涨0.96%,报1.57美元,成交额62.39万美元,市值2.32亿美元。 行情数据 • 开盘价:1.56美元 • 最...
10-27 06:36